Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
British Journal of Cancer|February 7, 2008
Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I-III nonsmall cell lung cancerK Kaira, N Oriuchi, H Imai, et al.
Neoplasma|February 15, 2012
¹⁸F-FDG uptake on PET could be a predictive marker of excision repair cross-complementation group 1 (ERCC1) expression in patients with thoracic neoplasms?K Kaira, M Endo, T Shukuya, et al.
British Journal of Cancer|March 1, 2014
Clinicopathological and prognostic significance of interleukin-8 expression and its relationship to KRAS mutation in lung adenocarcinomaN Sunaga, K Kaira, Y Tomizawa, et al.
British Journal of Cancer|April 26, 2014
Prognostic significance of amino-acid transporter expression (LAT1, ASCT2, and xCT) in surgically resected tongue cancerM Toyoda, K Kaira, Y Ohshima, et al.
Oncogene|September 12, 2012
Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancerN Sunaga, K Kaira, H Imai, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|May 21, 2015
Efficacy of platinum combination chemotherapy after first-line gefitinib treatment in non-small cell lung cancer patients harboring sensitive EGFR mutationsT Masuda, H Imai, T Kuwako, et al.
British Journal of Cancer|July 19, 2012
Prognostic significance of L-type amino-acid transporter 1 expression in surgically resected pancreatic cancerK Kaira, Y Sunose, K Arakawa, et al.
British Journal of Cancer|March 27, 2014
Biological significance of fluorine-18-α-methyltyrosine (FAMT) uptake on PET in patients with oesophageal cancerS Suzuki, K Kaira, Y Ohshima, et al.
ESMO Open|October 12, 2024
A phase II study of daily carboplatin plus irradiation followed by durvalumab therapy for older adults (≥75 years) with unresectable III non-small-cell lung cancer and performance status of 2: NEJ039AA Mouri, A Kisohara, R Morita, et al.
Pageof 2